文献速递其他结缔组织病

皮肌炎患者的COVID-19结局:一项基于登记数据库的队列分析

COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis.
PubMed 文献 · Semin Arthritis Rheum · 2022-05-28

基于TriNetX数据库的回顾性队列分析,纳入2020年1月至2021年8月皮肌炎合并COVID-19患者5574例与一般人群COVID-19对照5574例,经1:1倾向性评分匹配后,皮肌炎患者死亡、住院、重症COVID-19、急性肾损伤及脓毒症风险低于对照;男性、非裔美国人、间质性肺病、使用DMARDs及糖皮质激素与较差结局相关。

要点

  • 皮肌炎合并COVID-19患者死亡风险低于对照(RR 0.76),住院(RR 0.8)、重症COVID-19(RR 0.76)、急性肾损伤(RR 0.83)及脓毒症(RR 0.73)风险亦较低。
  • 男性及非裔美国人更易发生急性肾损伤(RR 1.35、1.65),非裔美国人重症COVID-19(RR 1.62)及静脉血栓栓塞(RR 1.54)风险更高。
  • 合并间质性肺病者重症COVID-19(RR 1.64)及静脉血栓栓塞(RR 2.06)风险更高;使用DMARDs及糖皮质激素者住院(RR 1.46、2.12)及脓毒症(RR 3.25、2.4)风险更高。

核心结论

  • 无合并症的皮肌炎患者COVID-19结局(包括死亡和住院)尚可。
  • 黑人种族、男性、间质性肺病、使用DMARDs及糖皮质激素与较差结局相关。

研究设计与样本

  • 回顾性队列分析,数据来自TriNetX数据库,纳入2020年1月至2021年8月皮肌炎合并COVID-19患者与一般人群COVID-19对照,采用1:1倾向性评分匹配调整混杂因素。
  • 共识别皮肌炎合并COVID-19患者5574例及一般人群COVID-19对照5574例。
  • 评估结局包括死亡、住院、ICU入住、重症COVID-19、机械通气、急性肾损伤、静脉血栓栓塞、缺血性卒中、急性呼吸窘迫综合征、肾脏替代治疗及脓毒症。
  • 亚组分析包括性别、种族、间质性肺病、肿瘤患者、DMARDs使用及糖皮质激素使用。

主要发现

  • 皮肌炎合并COVID-19患者较对照死亡风险更低(RR 0.76)、住院风险更低(RR 0.8)、重症COVID-19风险更低(RR 0.76)、急性肾损伤风险更低(RR 0.83)、脓毒症风险更低(RR 0.73)。
  • 男性发生急性肾损伤风险更高(RR 1.35),非裔美国人发生急性肾损伤风险更高(RR 1.65)。
  • 非裔美国人重症COVID-19风险更高(RR 1.62),静脉血栓栓塞风险更高(RR 1.54)。
  • 合并间质性肺病的皮肌炎患者重症COVID-19风险更高(RR 1.64),静脉血栓栓塞风险更高(RR 2.06)。
  • 使用DMARDs的皮肌炎患者住院风险更高(RR 1.46)、脓毒症风险更高(RR 3.25);使用糖皮质激素者住院风险更高(RR 2.12)、脓毒症风险更高(RR 2.4)。

关键数值与推荐

  • 皮肌炎合并COVID-19患者死亡风险RR 0.76,住院风险RR 0.8,重症COVID-19风险RR 0.76,急性肾损伤风险RR 0.83,脓毒症风险RR 0.73(均与一般人群COVID-19对照比较)。
  • 男性急性肾损伤风险RR 1.35,非裔美国人急性肾损伤风险RR 1.65、重症COVID-19风险RR 1.62、静脉血栓栓塞风险RR 1.54。
  • 合并间质性肺病者重症COVID-19风险RR 1.64、静脉血栓栓塞风险RR 2.06。
  • 使用DMARDs者住院风险RR 1.46、脓毒症风险RR 3.25;使用糖皮质激素者住院风险RR 2.12、脓毒症风险RR 2.4。
  • 皮肌炎合并COVID-19患者中5年肿瘤史亚组分析样本量不足以进行有意义的比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性数据研究。
  • 皮肌炎合并COVID-19患者中5年肿瘤史亚组分析不足以进行有意义的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with rheumatic diseases (RDs) like DM are known to be vulnerable towards various types of infections due to aggressive disease activity mandating high dose immunosuppressive therapy. The severity of COVID-19 in RDs is limited in literature due to the heterogeneous nature of the condition. Therefore, specific details on mortality is essential to navigate any precautions required in the treatment. OBJECTIVES: To determine outcomes of COVID-19 in DM as compared to controls, and identify the risk association of gender, race, interstitial lung disease, neoplasms, and use of immunosuppressant. METHODS: Retrospective data of individuals with DM and COVID-19 and the general population with COVID-19 between January 2020 to August 2021 was retrieved from the TriNetX database. 1:1 Propensity Score matching was used to adjust for confounders. We assessed COVID-19 outcomes such as mortality, hospitalisation, ICU admission, severe COVID-19, mechanical ventilation (MV), acute kidney injury (AKI), venous thromboembolism (VTE), ischemic stroke, acute respiratory distress syndrome (ARDS), renal replacement therapy (RRT) and sepsis. Subgroup analyses included gender, race, ILD, cancer patients, disease-modifying rheumatic drugs (DMARDs) use, and glucocorticoids (GC) use. RESULTS: We identified 5,574 DM patients with COVID-19, and 5,574 general population with COVID-19 (controls). DM with COVID-19 had a lower risk of mortality in comparison to controls [RR 0.76], hospitalisation [RR 0.8], severe COVID-19 [RR 0.76], AKI [RR 0.83], and sepsis [RR 0.73]. Males and African Americans were more likely to develop AKI [RR 1.35, 1.65], while African Americans had higher odds for severe COVID-19 [RR 1.62] and VTE [RR 1.54]. DM with ILD group also experienced higher odds for severe COVID-19 infection [RR 1.64], and VTE [RR 2.06]. DM patients receiving DMARDs and glucocorticoids had higher odds for hospitalisation [RR 1.46, 2.12], and sepsis [RR 3.25, 2.4] Subgroup analysis of 5-year neoplasm history amongst DM patients with COVID-19 was inadequate for meaningful comparison. CONCLUSION: Dermatomyositis patients without comorbities have reasonable COVID-19 outcomes including mortality and hospitalisation. Black race, male gender, ILD, DMARDS and glucocorticoid users, are associated with poor outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pakhchanian H, Khan H, Raiker R, et al. COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis. Semin Arthritis Rheum. 2022. PMID: 35750526. doi:10.1016/j.semarthrit.2022.152034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。